Mohs vs curettage and electrodesiccation: which fits your skin cancer?

For a small, low-risk basal or squamous cell carcinoma in an area with plenty of spare skin, curettage and electrodesiccation can be a quick, effective, single-visit treatment, but it never proves the margin is clear the way Mohs micrographic surgery does. Curettage and electrodesiccation, often shortened to ED&C or described as scrape-and-burn, removes the cancer in the office with no stitches, while Mohs is a longer, more thorough procedure reserved for tumors where complete margin control counts. Understanding how the two differ explains why the same diagnosis can lead to very different recommendations, much as it does when weighing Mohs against a standard excision.

Curettage and electrodesiccation works by feel, not by microscope. The surgeon numbs the skin, then uses a curette, a small spoon-shaped instrument with a sharp edge, to scrape away the soft, crumbly tumor tissue, which gives way more easily than the firm normal skin around it. An electric needle then burns the base to destroy any remaining cancer cells and stop bleeding. The scrape-and-burn cycle is usually repeated two or three times in the same sitting. The American Academy of Dermatology lists ED&C among the standard treatments for low-risk basal cell carcinoma. Its defining limitation is that no tissue is examined under a microscope: the surgeon judges when the cancer is gone by the difference in texture between tumor and healthy skin, not by proof.

Mohs answers the clearance question directly. Where ED&C infers success from feel, Mohs removes the tumor a thin layer at a time and reads essentially the entire margin under the microscope before the wound is closed, following the cancer wherever it actually reaches. That difference, verified clearance versus a texture-based estimate, is the root of the gap between the two techniques. A tumor that sends invisible roots past its apparent edge can be missed by a curette that only removes what feels soft, while complete margin examination is built to catch exactly those extensions in a single visit.

Cure rates favor Mohs, and the gap widens as risk rises. For carefully selected low-risk tumors in experienced hands, ED&C cure rates are often reported in the range of 90 to 95 percent, which is genuinely good for the right lesion. Mohs, by contrast, achieves cure rates commonly cited around 99 percent for primary basal cell carcinoma and roughly 97 percent for primary squamous cell carcinoma, and it holds that edge precisely because it inspects the whole margin rather than sampling or estimating it. As with any figure, what the cure rate really means is the near-certainty that no tumor remained at the edges on the day of treatment, which ED&C simply cannot confirm.

ED&C earns its place on low-risk tumors in forgiving locations. For a small, well-defined, superficial basal cell carcinoma on the trunk or a limb, where there is ample spare skin and the tumor is not aggressive, scrape-and-burn is fast, inexpensive, and effective, and it spares the patient a long procedure day. It can be a reasonable choice for patients with several low-risk lesions to treat, or for those who prefer to avoid stitches. The Mayo Clinic lists curettage and electrodesiccation among the accepted options for small skin cancers away from high-risk areas. In these settings, reaching for Mohs would be using a more elaborate tool than the tumor requires.

ED&C is the wrong tool when the stakes rise. Scrape-and-burn is not appropriate for tumors on the face and other high-risk locations such as the nose, ears, eyelids, and lips, where both the cosmetic result and the risk of leaving cancer behind are unacceptable. It is a poor fit for aggressive microscopic subtypes that extend in irregular, finger-like projections, for large or poorly defined tumors, and for cancers that have already come back. Hair-bearing skin is another caution, because tumor can track down follicles below the reach of the curette. The published Appropriate Use Criteria map tumor type, size, and location to whether Mohs is the recommended approach, and the tumors that fall outside ED&C's safe range are largely the same ones for which Mohs is the gold standard.

The scar tells a different story too. ED&C leaves an open wound that heals on its own over several weeks, typically forming a round, flat, slightly pale or depressed scar that can be lighter than the surrounding skin. On the trunk or a limb this is usually a fine trade for the speed and simplicity. On the face, that kind of scar and the uncertainty about clearance are exactly why guidelines steer toward Mohs, which closes the wound with a tailored repair once the margins are confirmed clear and tends to leave the smallest defect the tumor allowed.

How the choice actually gets made. The decision is not Mohs or ED&C in the abstract; it is a match between a specific tumor and the technique that fits it. Tumor type, size, location, microscopic subtype, and whether it is new or recurrent all feed the recommendation, which is why the same clinic will offer scrape-and-burn for one patient and a full Mohs day for another. When the answer is genuinely close, or when a lesion sits at the boundary between low and high risk, that is the moment to have the conversation with an experienced, fellowship-trained Mohs surgeon who can explain why one approach suits your particular cancer.

The honest summary for a patient weighing the two is that curettage and electrodesiccation is faster, cheaper, and perfectly appropriate for the right low-risk tumor, while Mohs offers the highest cure rate and proof of clearance for tumors where those things matter most. Neither is universally better; each has a lane. If your skin cancer is small, low risk, and on the body, ED&C may be all it needs. If it sits on the face, looks aggressive under the microscope, or has returned once already, the case for complete margin control is strong, just as it is when comparing Mohs with radiation therapy.

Related reading: Mohs surgery vs standard excision: what is the difference?